Tag: GlobeNewswire

Toronto, Ontario, Nov. 02, 2026 (GLOBE NEWSWIRE) — Atlas One Capital Corporation (TSXV: ACAP.P) (the “Corporation” or “Atlas One”), a capital pool company listed on the TSX Venture Exchange (“TSXV”), and Ramsden Metals Inc. (“Ramsden Metals” and, together with Atlas One, the “Parties”) are pleased to provide an update on their proposed business combination transaction (the “Proposed Transaction”) as previously announced on July 14, 2026. It is anticipated that the Proposed Transaction will constitute the qualifying transaction of Atlas One in accordance with Policy 2.4 – Capital Pool Companies of the Corporate Finance Manual (the “CPC Policy”) of the TSXV. The resulting company following the completion of the Proposed Transaction is referred to as the “Resulting Issuer”. All currency references used in this news release are in Canadian currency unless otherwise noted.

Definitive Agreement

The Parties are pleased to announce that they have entered into a definitive agreement dated October 30, 2026 (the “Definitive Agreement”) pursuant to which Atlas One will acquire all of the issued and outstanding securities of Ramsden Metals in exchange for the issuance of securities of Atlas One. As consideration for the acquisition of all of the outstanding common shares of Ramsden Metals (“Ramsden Shares”), holders of Ramsden Shares will receive one (1) post-Consolidation (as defined below) common share of Atlas One (each, a “Resulting Issuer Share”) for each one (1) Ramsden Share held at the time of the completion of the Proposed Transaction.

The Proposed Transaction will be completed by way of a three-cornered amalgamation among Atlas One, Ramsden Metals, and a wholly owned subsidiary of Atlas One, to be incorporated in the Province of Ontario by Atlas One, which will amalgamate (the “Amalgamation”) with Ramsden Metals (the amalgamated company shall hereinafter be referred to as “Amalco”). Pursuant to the Amalgamation, Atlas One shall acquire all of the issued and outstanding Ramsden Shares. The result of the foregoing shall be that, on completion of the Proposed Transaction, Amalco shall be a wholly owned subsidiary of the Resulting Issuer. Upon the completion of the Proposed Transaction, it is expected the Resulting Issuer will change its name to Ramsden Metals Ltd., or such other name as Ramsden Metals may determine (the “Name Change”), and the Resulting Issuer will be a mining issuer focused on exploration of the Eagle’s Nest Critical Metals Project.

Under the terms of the Definitive Agreement, Atlas One shall consolidate (the “Consolidation”) its outstanding common shares (the “Atlas Shares”) on a basis that results in the existing Atlas Shareholders collectively holding that number of post-Consolidation Atlas Shares equal to an agree value of Atlas (fixed at $325,000) divided by the offering price under the Concurrent Offering (as defined below); provided that if the Concurrent Offering is comprised solely of an offering of Ramsden Shares issued on a flow-through basis, the price used to determine the consolidation ratio shall be 70% of the offering price under the Concurrent Offering.

The Parties have agreed that the Proposed Transaction is conditional upon certain conditions precedent, including, but not limited to, the completion of the Concurrent Financing (as defined below), the Consolidation, Name Change and the receipt of all necessary regulatory and shareholder approvals, including the approval of the Amalgamation by the shareholders of Ramsden Metals.

There can be no assurance that the Proposed Transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the filing statement to be prepared in connection with the Proposed Transaction, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative. The TSXV has in no way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this news release.

Shareholder Approval

Atlas One shall hold an annual general and special shareholder meeting for the purposes of obtaining shareholder approval for the Name Change and Consolidation. Atlas One will not seek nor is it required to obtain securityholder approval of the Proposed Transaction pursuant to applicable securities laws or the policies of the TSXV. The Proposed Transaction is not a “Non-Arm’s Length Qualifying Transaction” as such term is defined in the CPC Policy. No Non-Arm’s Length Party to Atlas One (as such term is defined in the CPC Policy) (a) has any direct or indirect beneficial interest in Ramsden Metals, or (b) is an insider of Ramsden Metals. There is no relationship between or among a Non-Arm’s Length Party to Atlas One and a Non-Arm’s Length Party to the Qualifying Transaction (as such terms are defined in the CPC Policy).

Concurrent Financing 

The Proposed Transaction remains conditional upon an expected offering (the “Concurrent Financing”) of subscription receipts (the “Subscription Receipts”) by Ramsden Metals on such price, size and other terms as may be determined by Ramsden Metals and accepted by the TSXV, provided that following the Proposed Transaction the funds resulting to the Resulting Issuer are sufficient to satisfy the applicable financing and listing requirements of the TSXV.

It is expected that each Subscription Receipt will represent the right of a holder to receive, upon satisfaction or waiver of certain escrow release conditions, without payment of additional consideration, securities of Ramsden Metals in accordance with the terms and conditions of a subscription receipt agreement (the “Subscription Receipt Agreement”) to be entered into among the Parties and a subscription receipt and escrow agent upon closing of the Concurrent Financing.

Pursuant to the terms of the Proposed Transaction, the Concurrent Financing and the Subscription Receipt Agreement, any Ramsden Share issued upon conversion of the Subscription Receipts would be exchanged for one Resulting Issuer Share and any common share purchase warrant of Ramsden Metals issued upon conversion of the Subscription Receipts would be exchanged for one common share purchase warrant of the Resulting Issuer.

The Parties acknowledge that an agent may be engaged to act as agent on a “commercially reasonable efforts” basis for the Concurrent Financing, or finders may be engaged in connection with the Concurrent Financing, and in connection therewith may be paid a commission in an amount to be determined.

The Parties expect to announce the Concurrent Financing by news release upon launch of the same, and to include additional details and final terms of the Concurrent Financing in such news release.

The Resulting Issuer

The Parties expect that the Resulting Issuer following from the Proposed Transaction will carry on the existing business of Ramsden Metals and be a mineral exploration company focused on exploration of the Eagle’s Nest Critical Metals Project. See “Definitive Agreement” above for details concerning the expected corporate structure of the Resulting Issuer upon completion of the Proposed Transaction.

Trading Halt

The Atlas Shares are currently halted from trading and are not expected to resume trading until the Proposed Transaction is completed.

About Ramsden Metals

Ramsden Metals is a privately held Canadian mineral exploration company focused on identifying, acquiring and advancing critical-mineral opportunities in North America. Ramsden Metals’ principal asset is the Eagle’s Nest Critical Metals Project, an early-stage exploration property comprising approximately 51.25 square kilometres of mineral claims located approximately 125 kilometres north of Churchill Falls in central Labrador. The property is centred on the Michikamats intrusive complex and a prominent circular magnetic anomaly.

Information Concerning Atlas One

Atlas One is a capital pool company and the Atlas One Shares are listed for trading on the TSXV under the symbol “ACAP.P”.

For further information, please contact: 

David Rosenkrantz
President, CEO, CFO and Director at 416-865-0123

Information concerning Ramsden Metals, including the proposed directors of the Resulting Issuer, has been provided to the Corporation by Ramsden Metals for inclusion in this news release. The scientific and technical information concerning the Eagle’s Nest Critical Metals Project contained in this news release has been reviewed and approved by Dr. E. Max Baker, FAusIMM, Senior Geological Advisor to Ramsden Metals and a “qualified person” as defined in National Instrument 43-101 (“NI 43-101”) – Standards of Disclosure for Mineral Projects.

Completion of the Proposed Transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and if applicable pursuant to Exchange Requirements (as that term is defined in the policies of the TSXV), majority of the minority shareholder approval. Where applicable, the Proposed Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Proposed Transaction, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

The TSXV has in no way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. 

The securities referenced herein have not been, nor will be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from U.S. registration requirements. This release does not constitute an offer for sale of securities in the United States.

Cautionary and Forward-Looking Statements

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes”, “intends” or variations of such words and phrases or stating that certain actions, events or results “may”, “could, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the Proposed Transaction and certain terms and conditions thereof; the Consolidation; the Name Change; the anticipated listing of the Resulting Issuer on the TSXV; the business of Ramsden Metals; the exploration and advancement of the Eagle’s Nest Critical Metals Project; the Concurrent Financing and the anticipated use of proceeds therefrom; shareholder, director and regulatory approvals; and future news releases and disclosure. Forward looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors that may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; and the delay or failure to receive shareholder, director or regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, Atlas One assumes no obligation to update the forward-looking statements or beliefs, opinions, projections, or other factors, should they change.

Toronto, Ontario, Nov. 02, 2026 (GLOBE NEWSWIRE) — Atlas One Capital Corporation (TSXV: ACAP.P) (the “Corporation” or “Atlas One”), a capital pool company listed on the TSX Venture Exchange (“TSXV”), and Ramsden Metals Inc. (“Ramsden Metals” and, together with Atlas One, the “Parties”) are pleased to provide an update on their proposed business combination transaction (the “Proposed Transaction”) as previously announced on July 14, 2026. It is anticipated that the Proposed Transaction will constitute the qualifying transaction of Atlas One in accordance with Policy 2.4 – Capital Pool Companies of the Corporate Finance Manual (the “CPC Policy”) of the TSXV. The resulting company following the completion of the Proposed Transaction is referred to as the “Resulting Issuer”. All currency references used in this news release are in Canadian currency unless otherwise noted.

Definitive Agreement

The Parties are pleased to announce that they have entered into a definitive agreement dated October 30, 2026 (the “Definitive Agreement”) pursuant to which Atlas One will acquire all of the issued and outstanding securities of Ramsden Metals in exchange for the issuance of securities of Atlas One. As consideration for the acquisition of all of the outstanding common shares of Ramsden Metals (“Ramsden Shares”), holders of Ramsden Shares will receive one (1) post-Consolidation (as defined below) common share of Atlas One (each, a “Resulting Issuer Share”) for each one (1) Ramsden Share held at the time of the completion of the Proposed Transaction.

The Proposed Transaction will be completed by way of a three-cornered amalgamation among Atlas One, Ramsden Metals, and a wholly owned subsidiary of Atlas One, to be incorporated in the Province of Ontario by Atlas One, which will amalgamate (the “Amalgamation”) with Ramsden Metals (the amalgamated company shall hereinafter be referred to as “Amalco”). Pursuant to the Amalgamation, Atlas One shall acquire all of the issued and outstanding Ramsden Shares. The result of the foregoing shall be that, on completion of the Proposed Transaction, Amalco shall be a wholly owned subsidiary of the Resulting Issuer. Upon the completion of the Proposed Transaction, it is expected the Resulting Issuer will change its name to Ramsden Metals Ltd., or such other name as Ramsden Metals may determine (the “Name Change”), and the Resulting Issuer will be a mining issuer focused on exploration of the Eagle’s Nest Critical Metals Project.

Under the terms of the Definitive Agreement, Atlas One shall consolidate (the “Consolidation”) its outstanding common shares (the “Atlas Shares”) on a basis that results in the existing Atlas Shareholders collectively holding that number of post-Consolidation Atlas Shares equal to an agree value of Atlas (fixed at $325,000) divided by the offering price under the Concurrent Offering (as defined below); provided that if the Concurrent Offering is comprised solely of an offering of Ramsden Shares issued on a flow-through basis, the price used to determine the consolidation ratio shall be 70% of the offering price under the Concurrent Offering.

The Parties have agreed that the Proposed Transaction is conditional upon certain conditions precedent, including, but not limited to, the completion of the Concurrent Financing (as defined below), the Consolidation, Name Change and the receipt of all necessary regulatory and shareholder approvals, including the approval of the Amalgamation by the shareholders of Ramsden Metals.

There can be no assurance that the Proposed Transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the filing statement to be prepared in connection with the Proposed Transaction, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative. The TSXV has in no way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this news release.

Shareholder Approval

Atlas One shall hold an annual general and special shareholder meeting for the purposes of obtaining shareholder approval for the Name Change and Consolidation. Atlas One will not seek nor is it required to obtain securityholder approval of the Proposed Transaction pursuant to applicable securities laws or the policies of the TSXV. The Proposed Transaction is not a “Non-Arm’s Length Qualifying Transaction” as such term is defined in the CPC Policy. No Non-Arm’s Length Party to Atlas One (as such term is defined in the CPC Policy) (a) has any direct or indirect beneficial interest in Ramsden Metals, or (b) is an insider of Ramsden Metals. There is no relationship between or among a Non-Arm’s Length Party to Atlas One and a Non-Arm’s Length Party to the Qualifying Transaction (as such terms are defined in the CPC Policy).

Concurrent Financing 

The Proposed Transaction remains conditional upon an expected offering (the “Concurrent Financing”) of subscription receipts (the “Subscription Receipts”) by Ramsden Metals on such price, size and other terms as may be determined by Ramsden Metals and accepted by the TSXV, provided that following the Proposed Transaction the funds resulting to the Resulting Issuer are sufficient to satisfy the applicable financing and listing requirements of the TSXV.

It is expected that each Subscription Receipt will represent the right of a holder to receive, upon satisfaction or waiver of certain escrow release conditions, without payment of additional consideration, securities of Ramsden Metals in accordance with the terms and conditions of a subscription receipt agreement (the “Subscription Receipt Agreement”) to be entered into among the Parties and a subscription receipt and escrow agent upon closing of the Concurrent Financing.

Pursuant to the terms of the Proposed Transaction, the Concurrent Financing and the Subscription Receipt Agreement, any Ramsden Share issued upon conversion of the Subscription Receipts would be exchanged for one Resulting Issuer Share and any common share purchase warrant of Ramsden Metals issued upon conversion of the Subscription Receipts would be exchanged for one common share purchase warrant of the Resulting Issuer.

The Parties acknowledge that an agent may be engaged to act as agent on a “commercially reasonable efforts” basis for the Concurrent Financing, or finders may be engaged in connection with the Concurrent Financing, and in connection therewith may be paid a commission in an amount to be determined.

The Parties expect to announce the Concurrent Financing by news release upon launch of the same, and to include additional details and final terms of the Concurrent Financing in such news release.

The Resulting Issuer

The Parties expect that the Resulting Issuer following from the Proposed Transaction will carry on the existing business of Ramsden Metals and be a mineral exploration company focused on exploration of the Eagle’s Nest Critical Metals Project. See “Definitive Agreement” above for details concerning the expected corporate structure of the Resulting Issuer upon completion of the Proposed Transaction.

Trading Halt

The Atlas Shares are currently halted from trading and are not expected to resume trading until the Proposed Transaction is completed.

About Ramsden Metals

Ramsden Metals is a privately held Canadian mineral exploration company focused on identifying, acquiring and advancing critical-mineral opportunities in North America. Ramsden Metals’ principal asset is the Eagle’s Nest Critical Metals Project, an early-stage exploration property comprising approximately 51.25 square kilometres of mineral claims located approximately 125 kilometres north of Churchill Falls in central Labrador. The property is centred on the Michikamats intrusive complex and a prominent circular magnetic anomaly.

Information Concerning Atlas One

Atlas One is a capital pool company and the Atlas One Shares are listed for trading on the TSXV under the symbol “ACAP.P”.

For further information, please contact: 

David Rosenkrantz
President, CEO, CFO and Director at 416-865-0123

Information concerning Ramsden Metals, including the proposed directors of the Resulting Issuer, has been provided to the Corporation by Ramsden Metals for inclusion in this news release. The scientific and technical information concerning the Eagle’s Nest Critical Metals Project contained in this news release has been reviewed and approved by Dr. E. Max Baker, FAusIMM, Senior Geological Advisor to Ramsden Metals and a “qualified person” as defined in National Instrument 43-101 (“NI 43-101”) – Standards of Disclosure for Mineral Projects.

Completion of the Proposed Transaction is subject to a number of conditions, including but not limited to, TSXV acceptance and if applicable pursuant to Exchange Requirements (as that term is defined in the policies of the TSXV), majority of the minority shareholder approval. Where applicable, the Proposed Transaction cannot close until the required shareholder approval is obtained. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Proposed Transaction, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

The TSXV has in no way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. 

The securities referenced herein have not been, nor will be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent U.S. registration or an applicable exemption from U.S. registration requirements. This release does not constitute an offer for sale of securities in the United States.

Cautionary and Forward-Looking Statements

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes”, “intends” or variations of such words and phrases or stating that certain actions, events or results “may”, “could, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements relate, among other things, to: the Proposed Transaction and certain terms and conditions thereof; the Consolidation; the Name Change; the anticipated listing of the Resulting Issuer on the TSXV; the business of Ramsden Metals; the exploration and advancement of the Eagle’s Nest Critical Metals Project; the Concurrent Financing and the anticipated use of proceeds therefrom; shareholder, director and regulatory approvals; and future news releases and disclosure. Forward looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors that may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; and the delay or failure to receive shareholder, director or regulatory approvals. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release. Except as required by law, Atlas One assumes no obligation to update the forward-looking statements or beliefs, opinions, projections, or other factors, should they change.

YYForce presents its reported book equity alongside its market capitalization to give investors additional context for its growth plans

SINGAPORE, Nov. 02, 2026 (GLOBE NEWSWIRE) — YYForce Inc. (Nasdaq: YFOR) (“YYForce” or the “Company”), a technology-enabled provider of workforce solutions and integrated facility management services, today highlighted its reported net assets of approximately US$21.9 million, compared with an estimated market capitalization of approximately US$2.1 million as of October 30, 2026, and outlined its commercial robotics and AI priorities.

YYForce is providing this information to help investors evaluate its reported asset base alongside its operating results, liquidity and strategy across workforce platforms, integrated facility management and service robotics.

Reported financial position and valuation comparison

As reported in the Company’s Form 6-K filed on September 25, 2026, YYForce’s consolidated balance sheet as of June 30, 2026, showed the following amounts.

Balance sheet measure	Reported amount
Total assets	Approximately US$38 million
Equity attributable to YYForce shareholders (net assets)	Approximately US$21.9 million

As of October 30, 2026, the Company’s estimated equity market capitalization was approximately US$2.1 million, equivalent to approximately 9.6% of reported equity attributable to YYForce shareholders. This represented a discount of approximately 90.4% to reported book equity. This information uses rounded amounts and reflects financial and market data from different dates.

Book equity does not represent unrestricted cash, tangible net assets, liquidation proceeds or an estimate of intrinsic value. Asset carrying values are subject to accounting estimates and impairment assessments. Investors should consider the full financial statements, including liabilities, operating results, cash flows and subsequent disclosures.

Management commentary

“We believe the difference between our reported book equity and public market capitalization warrants investors’ attention,” said Mike Fu, Chief Executive Officer of YYForce. “Our responsibility is to provide clear financial information and execute our commercial strategy. We remain focused on customer delivery, disciplined capital allocation and developing our workforce, facility management and service robotics businesses.”

“We will evaluate each investment against customer demand, available liquidity, capital requirements and expected returns,” Mr. Fu added.

Strategic growth priorities

Commercial robotics expansion. Pursuing service robotics deployments and integration with hospitality and enterprise workflows, with attention to customer requirements, deployment costs and ongoing support.

AI-enabled facility and workforce platforms. Developing digital platform capabilities and pursuing enterprise adoption to support workforce coordination, shift delivery and facility operations.

Capital discipline and market transparency. Evaluating commercial deployments against customer demand, capital requirements and expected returns, while providing shareholders with clear updates on material developments.

YYForce will continue to assess its operating performance, financing requirements and capital allocation priorities as its business develops. Future commercial progress remains subject to operational execution, customer adoption and broader market conditions.

About YYForce Inc.

YYForce Inc. (Nasdaq: YFOR) is a technology-enabled provider of workforce solutions and integrated facility management services. The Company is developing AI-enabled workforce platforms and robotics capabilities to support frontline operations, improve productivity and address evolving customer needs.

For more information, visit www.yyforce.ai.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on the Company’s current expectations, assumptions and information available to it as of the date of this release. Forward-looking statements can be identified by words such as “may,” “will,” “should,” “expects,” “anticipates,” “plans,” “intends,” “believes,” “estimates,” “potential” or similar expressions, or the negative of these terms.

Forward-looking statements in this release include, but are not limited to, expectations regarding the Company’s strategy, commercial deployments, platform development, operational efficiency, capital allocation and future business performance. Historical financial figures are not forward-looking statements. Reported book equity is not an indication of the price at which the Company’s shares may trade or of amounts that would be realized on any sale or liquidation.

Forward-looking statements involve inherent risks and uncertainties, and the forward-looking events discussed in this press release may not occur, actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about the Company and a number of factors. For a more detailed discussion of risk factors, please refer to the Company’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” section of the Company’s most recent annual report on Form 20-F, as amended. YYForce undertakes no obligation to update these statements except as required by applicable law.

Investor Relations Contact

YYForce Inc.
Investor Relations Department
Email: ir@yyforce.ai
Website: www.yyforce.ai

YYForce presents its reported book equity alongside its market capitalization to give investors additional context for its growth plans

SINGAPORE, Nov. 02, 2026 (GLOBE NEWSWIRE) — YYForce Inc. (Nasdaq: YFOR) (“YYForce” or the “Company”), a technology-enabled provider of workforce solutions and integrated facility management services, today highlighted its reported net assets of approximately US$21.9 million, compared with an estimated market capitalization of approximately US$2.1 million as of October 30, 2026, and outlined its commercial robotics and AI priorities.

YYForce is providing this information to help investors evaluate its reported asset base alongside its operating results, liquidity and strategy across workforce platforms, integrated facility management and service robotics.

Reported financial position and valuation comparison

As reported in the Company’s Form 6-K filed on September 25, 2026, YYForce’s consolidated balance sheet as of June 30, 2026, showed the following amounts.

Balance sheet measure	Reported amount
Total assets	Approximately US$38 million
Equity attributable to YYForce shareholders (net assets)	Approximately US$21.9 million

As of October 30, 2026, the Company’s estimated equity market capitalization was approximately US$2.1 million, equivalent to approximately 9.6% of reported equity attributable to YYForce shareholders. This represented a discount of approximately 90.4% to reported book equity. This information uses rounded amounts and reflects financial and market data from different dates.

Book equity does not represent unrestricted cash, tangible net assets, liquidation proceeds or an estimate of intrinsic value. Asset carrying values are subject to accounting estimates and impairment assessments. Investors should consider the full financial statements, including liabilities, operating results, cash flows and subsequent disclosures.

Management commentary

“We believe the difference between our reported book equity and public market capitalization warrants investors’ attention,” said Mike Fu, Chief Executive Officer of YYForce. “Our responsibility is to provide clear financial information and execute our commercial strategy. We remain focused on customer delivery, disciplined capital allocation and developing our workforce, facility management and service robotics businesses.”

“We will evaluate each investment against customer demand, available liquidity, capital requirements and expected returns,” Mr. Fu added.

Strategic growth priorities

Commercial robotics expansion. Pursuing service robotics deployments and integration with hospitality and enterprise workflows, with attention to customer requirements, deployment costs and ongoing support.

AI-enabled facility and workforce platforms. Developing digital platform capabilities and pursuing enterprise adoption to support workforce coordination, shift delivery and facility operations.

Capital discipline and market transparency. Evaluating commercial deployments against customer demand, capital requirements and expected returns, while providing shareholders with clear updates on material developments.

YYForce will continue to assess its operating performance, financing requirements and capital allocation priorities as its business develops. Future commercial progress remains subject to operational execution, customer adoption and broader market conditions.

About YYForce Inc.

YYForce Inc. (Nasdaq: YFOR) is a technology-enabled provider of workforce solutions and integrated facility management services. The Company is developing AI-enabled workforce platforms and robotics capabilities to support frontline operations, improve productivity and address evolving customer needs.

For more information, visit www.yyforce.ai.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on the Company’s current expectations, assumptions and information available to it as of the date of this release. Forward-looking statements can be identified by words such as “may,” “will,” “should,” “expects,” “anticipates,” “plans,” “intends,” “believes,” “estimates,” “potential” or similar expressions, or the negative of these terms.

Forward-looking statements in this release include, but are not limited to, expectations regarding the Company’s strategy, commercial deployments, platform development, operational efficiency, capital allocation and future business performance. Historical financial figures are not forward-looking statements. Reported book equity is not an indication of the price at which the Company’s shares may trade or of amounts that would be realized on any sale or liquidation.

Forward-looking statements involve inherent risks and uncertainties, and the forward-looking events discussed in this press release may not occur, actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about the Company and a number of factors. For a more detailed discussion of risk factors, please refer to the Company’s filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” section of the Company’s most recent annual report on Form 20-F, as amended. YYForce undertakes no obligation to update these statements except as required by applicable law.

Investor Relations Contact

YYForce Inc.
Investor Relations Department
Email: ir@yyforce.ai
Website: www.yyforce.ai

Full-scale entry into the Middle East is set for the first half of 2027, with Africa to follow in mid-2027

SHANGHAI, Nov. 02, 2026 (GLOBE NEWSWIRE) — FREELANDER is moving ahead with its roll-out in the Middle East and Africa. The brand plans to cover 11 Middle East markets, with a full-scale entry into the region set for the first half of 2027. It will enter Africa through Morocco, with Morocco and Tunisia among its first African markets.

Two FREELANDER 8 vehicles on a desert road

From Brand Presentation to Sales and Service

The 11 markets are the UAE, Kuwait, Qatar, Saudi Arabia, Israel, Iraq, Jordan, Lebanon, Bahrain, Oman and Egypt. As the starting point of FREELANDER’s international business, the region is now moving from brand presentations and partnership talks to preparing sales and service networks.

In the UAE, Al Tayer Motors and Premier Motors are FREELANDER’s official dealer partners. At FREELANDER Nightfall, held during the 2026 Chery International User Summit in Wuhu in October, the brand signed new partnership agreements for Bahrain and Oman. FREELANDER 8 is expected to launch in the UAE in the first quarter of 2027.

“For me, bringing FREELANDER to the world means more than entering new markets. It means earning the trust of our customers, every day. That takes a great product, strong local partners and service people can rely on,” said Ms Lucia Mao, CEO of FREELANDER International, at FREELANDER Nightfall.

Ms Lucia Mao, CEO of FREELANDER International, speaks at FREELANDER Nightfall

Morocco Opens the Way into Africa

In Africa, Morocco will be FREELANDER’s first step and, together with Tunisia, will form the brand’s first group of African markets. Preparations are actively under way, with entry expected in mid-2027. FREELANDER will work with prospective local partners on sales, after-sales and product introduction plans suited to each market.

Entry timing, specifications, pricing and sales arrangements for each market will be announced through official channels.

About FREELANDER

FREELANDER is a British Premium Intelligent All-Terrain Brand, jointly developed by JLR and Chery Group. JLR owns the FREELANDER brand and has established a dedicated FREELANDER Design Hub to lead its design. Chery provides advanced intelligent technology and a top-tier global supply chain. The brand’s global foundation includes more than 5,000 employees, five strategic hubs and fully integrated capabilities spanning design, R&D, manufacturing and global operations.

Media contact
Daniel Bao
freelander.international@mychery.com
https://www.cheryinternational.com/

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/cc04767d-8d98-4b52-b9ff-2acda35c0909

https://www.globenewswire.com/NewsRoom/AttachmentNg/dfba34fe-910c-4b8f-bba8-5c4be88d691c

Full-scale entry into the Middle East is set for the first half of 2027, with Africa to follow in mid-2027

SHANGHAI, Nov. 02, 2026 (GLOBE NEWSWIRE) — FREELANDER is moving ahead with its roll-out in the Middle East and Africa. The brand plans to cover 11 Middle East markets, with a full-scale entry into the region set for the first half of 2027. It will enter Africa through Morocco, with Morocco and Tunisia among its first African markets.

Two FREELANDER 8 vehicles on a desert road

From Brand Presentation to Sales and Service

The 11 markets are the UAE, Kuwait, Qatar, Saudi Arabia, Israel, Iraq, Jordan, Lebanon, Bahrain, Oman and Egypt. As the starting point of FREELANDER’s international business, the region is now moving from brand presentations and partnership talks to preparing sales and service networks.

In the UAE, Al Tayer Motors and Premier Motors are FREELANDER’s official dealer partners. At FREELANDER Nightfall, held during the 2026 Chery International User Summit in Wuhu in October, the brand signed new partnership agreements for Bahrain and Oman. FREELANDER 8 is expected to launch in the UAE in the first quarter of 2027.

“For me, bringing FREELANDER to the world means more than entering new markets. It means earning the trust of our customers, every day. That takes a great product, strong local partners and service people can rely on,” said Ms Lucia Mao, CEO of FREELANDER International, at FREELANDER Nightfall.

Ms Lucia Mao, CEO of FREELANDER International, speaks at FREELANDER Nightfall

Morocco Opens the Way into Africa

In Africa, Morocco will be FREELANDER’s first step and, together with Tunisia, will form the brand’s first group of African markets. Preparations are actively under way, with entry expected in mid-2027. FREELANDER will work with prospective local partners on sales, after-sales and product introduction plans suited to each market.

Entry timing, specifications, pricing and sales arrangements for each market will be announced through official channels.

About FREELANDER

FREELANDER is a British Premium Intelligent All-Terrain Brand, jointly developed by JLR and Chery Group. JLR owns the FREELANDER brand and has established a dedicated FREELANDER Design Hub to lead its design. Chery provides advanced intelligent technology and a top-tier global supply chain. The brand’s global foundation includes more than 5,000 employees, five strategic hubs and fully integrated capabilities spanning design, R&D, manufacturing and global operations.

Media contact
Daniel Bao
freelander.international@mychery.com
https://www.cheryinternational.com/

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/cc04767d-8d98-4b52-b9ff-2acda35c0909

https://www.globenewswire.com/NewsRoom/AttachmentNg/dfba34fe-910c-4b8f-bba8-5c4be88d691c

SHANGHAI, Nov. 02, 2026 (GLOBE NEWSWIRE) — The international five-seat version of FREELANDER 8, the premium intelligent all-terrain SUV from the British brand FREELANDER, made its first public appearance last month at FREELANDER Nightfall, the brand’s evening at the 2026 Chery International User Summit in Wuhu. It was shown alongside the six-seat model.

FREELANDER 8 on display at the entrance to FREELANDER Nightfall at the Hengli Hotel in Wuhu

A Familiar Face, Made Modern

The Castle-Style Body Design, Dual-Peak Hood and Iconic Triangle Window carry FREELANDER 8’s British design heritage and link it to the original Freelander launched in 1997. “You can see the family look: simple surfaces, soft lines, a friendly face. FREELANDER 8 keeps that spirit — but it is bigger, more modern and more premium,” said Mr Phil Simmons, EVP of the FREELANDER Design Hub, who was part of the team that designed the original Freelander.

FREELANDER 8 on display, showing its Castle-Style Body Design, Dual-Peak Hood and Iconic Triangle Window

Five-Seat and Six-Seat Options

FREELANDER 8 comes in five-seat and six-seat layouts. The six-seat version provides three rows of seating, with a third row designed for adults, while the five-seat version offers two rows. The cabin is built for family and shared journeys.

After a test drive on the paved test course, a guest from the United Kingdom found the car “far more comfortable than I had expected.” FREELANDER 8 is expected to launch in the UAE in the first quarter of 2027. It brings together British Craftsmanship, Smart Confidence and All-Terrain Freedom, with i-ATS (Intelligent All-Terrain System) at the core of its all-terrain capability. Equipment and availability vary by market.

The two-row cabin of the five-seat FREELANDER 8

About FREELANDER

FREELANDER is a British Premium Intelligent All-Terrain Brand, jointly developed by JLR and Chery Group. JLR owns the FREELANDER brand and has established a dedicated FREELANDER Design Hub to lead its design. Chery provides advanced intelligent technology and a top-tier global supply chain. The brand’s global foundation includes more than 5,000 employees, five strategic hubs and fully integrated capabilities spanning design, R&D, manufacturing and global operations.

Media contact
Daniel Bao
freelander.international@mychery.com
https://www.cheryinternational.com/

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/4a65e954-d1f8-4d96-ae86-1accddbb6667

https://www.globenewswire.com/NewsRoom/AttachmentNg/c192f0d4-eb42-4739-b63a-7dfc01dd9ad0

https://www.globenewswire.com/NewsRoom/AttachmentNg/4b924977-c182-4141-b348-fcfb151e5ef3

SHANGHAI, Nov. 02, 2026 (GLOBE NEWSWIRE) — The international five-seat version of FREELANDER 8, the premium intelligent all-terrain SUV from the British brand FREELANDER, made its first public appearance last month at FREELANDER Nightfall, the brand’s evening at the 2026 Chery International User Summit in Wuhu. It was shown alongside the six-seat model.

FREELANDER 8 on display at the entrance to FREELANDER Nightfall at the Hengli Hotel in Wuhu

A Familiar Face, Made Modern

The Castle-Style Body Design, Dual-Peak Hood and Iconic Triangle Window carry FREELANDER 8’s British design heritage and link it to the original Freelander launched in 1997. “You can see the family look: simple surfaces, soft lines, a friendly face. FREELANDER 8 keeps that spirit — but it is bigger, more modern and more premium,” said Mr Phil Simmons, EVP of the FREELANDER Design Hub, who was part of the team that designed the original Freelander.

FREELANDER 8 on display, showing its Castle-Style Body Design, Dual-Peak Hood and Iconic Triangle Window

Five-Seat and Six-Seat Options

FREELANDER 8 comes in five-seat and six-seat layouts. The six-seat version provides three rows of seating, with a third row designed for adults, while the five-seat version offers two rows. The cabin is built for family and shared journeys.

After a test drive on the paved test course, a guest from the United Kingdom found the car “far more comfortable than I had expected.” FREELANDER 8 is expected to launch in the UAE in the first quarter of 2027. It brings together British Craftsmanship, Smart Confidence and All-Terrain Freedom, with i-ATS (Intelligent All-Terrain System) at the core of its all-terrain capability. Equipment and availability vary by market.

The two-row cabin of the five-seat FREELANDER 8

About FREELANDER

FREELANDER is a British Premium Intelligent All-Terrain Brand, jointly developed by JLR and Chery Group. JLR owns the FREELANDER brand and has established a dedicated FREELANDER Design Hub to lead its design. Chery provides advanced intelligent technology and a top-tier global supply chain. The brand’s global foundation includes more than 5,000 employees, five strategic hubs and fully integrated capabilities spanning design, R&D, manufacturing and global operations.

Media contact
Daniel Bao
freelander.international@mychery.com
https://www.cheryinternational.com/

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/4a65e954-d1f8-4d96-ae86-1accddbb6667

https://www.globenewswire.com/NewsRoom/AttachmentNg/c192f0d4-eb42-4739-b63a-7dfc01dd9ad0

https://www.globenewswire.com/NewsRoom/AttachmentNg/4b924977-c182-4141-b348-fcfb151e5ef3

~ FDA sets PDUFA target action date of May 1, 2027 ~

~ If approved, ifezuntirgene inilparvovec will be the world’s first disease-modifying treatment
for Huntington’s disease ~

LEXINGTON, Mass. and AMSTERDAM, Nov. 02, 2026 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington’s disease submitted under the Accelerated Approval pathway. The application has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027.

In its acceptance letter, the FDA stated that they are tentatively planning to discuss this application at an Advisory Committee meeting.  The Company will be notified once the date and timelines have been finalized.  

“The FDA’s acceptance of our BLA for review marks an important milestone for the Huntington’s disease community, which has waited generations for a treatment that changes the course of this devastating disease,” stated Matt Kapusta, chief executive officer of uniQure. “Backed by compelling data from our Phase I/II studies, we believe ifezuntirgene inilparvovec has the potential to become the first disease modifying treatment for Huntington’s disease. With the FDA’s priority review underway, we will work in conjunction with the Agency, clinicians, and the Huntington’s community to support the review process.   The confirmatory trial remains a key priority, with screening anticipated to begin by year end and the study is expected to be well underway by the time of potential approval.”

The BLA is supported by the previously announced 36-month data analysis from the Phase I/II clinical study of ifezuntirgene inilparvovec, compared to a propensity score-matched external control derived from the Enroll-HD natural history database, as previously announced on September 24, 2025.

The Company and FDA have aligned on key elements of the confirmatory study design. The study is designed as a randomized, standard-of-care trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with Total Functional Capacity (TFC) as the primary endpoint at 36 months. The Company plans to initiate patient screening in the U.S. by the end of 2026.

Ifezuntirgene inilparvovec is the first investigational therapy for Huntington’s disease to have received Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. Ifezuntirgene inilparvovec also holds Fast Track designation from the FDA.

About Ifezuntirgene Inilparvovec (AMT-130)

Ifezuntirgene inilparvovec is a novel gene therapy candidate for the treatment of Huntington’s disease, which utilizes a proprietary, gene-silencing miQURE^® platform and incorporates a miRNA, specifically designed to silence the huntingtin gene and the potentially highly toxic exon 1 protein fragment. Treated patients receive a single administration through targeted, MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).

About the Phase I/II Clinical Program of Ifezuntirgene Inilparvovec

uniQure is conducting two multi-center Phase I/II clinical studies evaluating the safety, tolerability, and efficacy of ifezuntirgene inilparvovec for the treatment of Huntington’s disease.

In total, the Phase I/II clinical studies have dosed 51 patients with ifezuntirgene inilparvovec. The U.S. randomized study enrolled 26 patients who received either a single administration of ifezuntirgene inilparvovec (n=6 low dose; n=10 high dose) or a sham procedure (n=10); four control patients subsequently crossed over to treatment after approximately 12 months. The European open-label study enrolled 13 patients (n=6 low dose; n=7 high dose). A third cohort of 12 patients explored both doses in combination with immunosuppression, and a fourth cohort of six U.S. patients is evaluating the high dose in patients with lower striatal volumes compared to those enrolled in previous cohorts.

Additional details are available on www.clinicaltrials.gov (NCT05243017, NCT04120493)

About Huntington’s Disease

Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities and cognitive decline resulting in progressive physical and mental deterioration. The disease is an autosomal dominant condition with a disease-causing CAG repeat expansion in the first exon of the huntingtin gene that leads to the production and aggregation of abnormal protein in the brain. Approximately 75,000 people have Huntington’s disease in the U.S.¹, EU², and the UK³, with hundreds of thousands of others at risk of inheriting the disease. Despite the clear etiology of Huntington’s disease, there are currently no approved therapies to delay the onset or to slow the disease’s progression.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington’s disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com

uniQure Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “expect,” “intend,” “look forward to,” “may,” “plan,” “potential,” “seek,” “should,” “will” and similar expressions and the negatives of those terms. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this report. Examples of these forward-looking statements include, but are not limited to, statements concerning: the Company’s beliefs related to the review and approval of its biologics license application (“BLA”) for ifezuntirgene inilparvovec; expectations regarding the adequacy of clinical data to support the marketing application and approval of ifezuntirgene inilparvovec; expectations regarding timing of receiving potential approval of, ifezuntirgene inilparvovec; whether the FDA will hold an advisory committee to discuss the BLA and the timing of such review and approval based on the Prescription Drug User Fee Act (“PDUFA”) target action date of May 1, 2027 for the BLA; and its belief related to the potential for ifezuntirgene inilparvovec, if approved, to meaningfully reduce disease progression   based on the Company’s evaluation and view of certain measurements of disease progression. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, among others: the risk that the FDA ultimately concludes that the Phase I/II trial data and/or the confirmatory trial data are not sufficient to support accelerated approval; the risk that more patient data become available that results in a different interpretation than the one derived from the year three and four data analyses, respectively; risks related to the Company’s interactions with regulatory authorities, which may affect the pathways to regulatory approval; whether RMAT designation, Breakthrough Therapy designation, or any accelerated pathway, if granted, will lead to regulatory approval; the Company’s ability to conduct and fund any required confirmatory study for ifezuntirgene inilparvovec; the Company’s ability to successfully complete any required confirmatory study for ifezuntirgene inilparvovec; the risk that accelerated approval, if granted, may be subject to post-approval requirements that are difficult or costly to satisfy; and the Company’s ability to continue to build and maintain the infrastructure and personnel needed to commercialize ifezuntirgene inilparvovec, if approved. These risks and uncertainties are more fully described under the heading “Risk Factors” in the Company’s periodic filings with the U.S. Securities & Exchange Commission (“SEC”), including its Annual Report on Form 10-K filed with the SEC on March 2, 2026, its Quarterly Report on Forms 10-Q filed with the SEC on May 5, 2026 and July 29, 2026, respectively, and in other filings that the Company makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements and, except as required by law, the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:

FOR INVESTORS:	FOR MEDIA:
Chiara Russo	Tom Malone
Direct: 781-491-4371	Direct: 339-970-7558
Mobile: 617-306-9137	Mobile:339-223-8541
c.russo@uniQure.com	t.malone@uniQure.com

---

¹ Yohrling G, et al. Neurology 2020;94(15 Suppl):954.
² Medina A, et al. Mov Disord 2022;37(12):2327–2335
³ Furby H, et al. Eur J Neurol 2022;29(8):2249–2257.

~ FDA sets PDUFA target action date of May 1, 2027 ~

~ If approved, ifezuntirgene inilparvovec will be the world’s first disease-modifying treatment
for Huntington’s disease ~

LEXINGTON, Mass. and AMSTERDAM, Nov. 02, 2026 (GLOBE NEWSWIRE) — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington’s disease submitted under the Accelerated Approval pathway. The application has been granted Priority Review with a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027.

In its acceptance letter, the FDA stated that they are tentatively planning to discuss this application at an Advisory Committee meeting.  The Company will be notified once the date and timelines have been finalized.  

“The FDA’s acceptance of our BLA for review marks an important milestone for the Huntington’s disease community, which has waited generations for a treatment that changes the course of this devastating disease,” stated Matt Kapusta, chief executive officer of uniQure. “Backed by compelling data from our Phase I/II studies, we believe ifezuntirgene inilparvovec has the potential to become the first disease modifying treatment for Huntington’s disease. With the FDA’s priority review underway, we will work in conjunction with the Agency, clinicians, and the Huntington’s community to support the review process.   The confirmatory trial remains a key priority, with screening anticipated to begin by year end and the study is expected to be well underway by the time of potential approval.”

The BLA is supported by the previously announced 36-month data analysis from the Phase I/II clinical study of ifezuntirgene inilparvovec, compared to a propensity score-matched external control derived from the Enroll-HD natural history database, as previously announced on September 24, 2025.

The Company and FDA have aligned on key elements of the confirmatory study design. The study is designed as a randomized, standard-of-care trial enrolling approximately 200 patients in a 2:1 ratio of ifezuntirgene inilparvovec to standard of care, with Total Functional Capacity (TFC) as the primary endpoint at 36 months. The Company plans to initiate patient screening in the U.S. by the end of 2026.

Ifezuntirgene inilparvovec is the first investigational therapy for Huntington’s disease to have received Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. Ifezuntirgene inilparvovec also holds Fast Track designation from the FDA.

About Ifezuntirgene Inilparvovec (AMT-130)

Ifezuntirgene inilparvovec is a novel gene therapy candidate for the treatment of Huntington’s disease, which utilizes a proprietary, gene-silencing miQURE^® platform and incorporates a miRNA, specifically designed to silence the huntingtin gene and the potentially highly toxic exon 1 protein fragment. Treated patients receive a single administration through targeted, MRI-guided, convection-enhanced stereotactic neurosurgical delivery directly into the striatum (caudate and putamen).

About the Phase I/II Clinical Program of Ifezuntirgene Inilparvovec

uniQure is conducting two multi-center Phase I/II clinical studies evaluating the safety, tolerability, and efficacy of ifezuntirgene inilparvovec for the treatment of Huntington’s disease.

In total, the Phase I/II clinical studies have dosed 51 patients with ifezuntirgene inilparvovec. The U.S. randomized study enrolled 26 patients who received either a single administration of ifezuntirgene inilparvovec (n=6 low dose; n=10 high dose) or a sham procedure (n=10); four control patients subsequently crossed over to treatment after approximately 12 months. The European open-label study enrolled 13 patients (n=6 low dose; n=7 high dose). A third cohort of 12 patients explored both doses in combination with immunosuppression, and a fourth cohort of six U.S. patients is evaluating the high dose in patients with lower striatal volumes compared to those enrolled in previous cohorts.

Additional details are available on www.clinicaltrials.gov (NCT05243017, NCT04120493)

About Huntington’s Disease

Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities and cognitive decline resulting in progressive physical and mental deterioration. The disease is an autosomal dominant condition with a disease-causing CAG repeat expansion in the first exon of the huntingtin gene that leads to the production and aggregation of abnormal protein in the brain. Approximately 75,000 people have Huntington’s disease in the U.S.¹, EU², and the UK³, with hundreds of thousands of others at risk of inheriting the disease. Despite the clear etiology of Huntington’s disease, there are currently no approved therapies to delay the onset or to slow the disease’s progression.

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. The approvals of uniQure’s gene therapy for hemophilia B – an historic achievement based on more than a decade of research and clinical development – represent a major milestone in the field of genomic medicine and ushers in a new treatment approach for patients living with hemophilia. uniQure is now advancing a pipeline of proprietary gene therapies for the treatment of patients with Huntington’s disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases. www.uniQure.com

uniQure Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “expect,” “intend,” “look forward to,” “may,” “plan,” “potential,” “seek,” “should,” “will” and similar expressions and the negatives of those terms. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this report. Examples of these forward-looking statements include, but are not limited to, statements concerning: the Company’s beliefs related to the review and approval of its biologics license application (“BLA”) for ifezuntirgene inilparvovec; expectations regarding the adequacy of clinical data to support the marketing application and approval of ifezuntirgene inilparvovec; expectations regarding timing of receiving potential approval of, ifezuntirgene inilparvovec; whether the FDA will hold an advisory committee to discuss the BLA and the timing of such review and approval based on the Prescription Drug User Fee Act (“PDUFA”) target action date of May 1, 2027 for the BLA; and its belief related to the potential for ifezuntirgene inilparvovec, if approved, to meaningfully reduce disease progression   based on the Company’s evaluation and view of certain measurements of disease progression. The Company’s actual results could differ materially from those anticipated in these forward-looking statements for many reasons. These risks and uncertainties include, among others: the risk that the FDA ultimately concludes that the Phase I/II trial data and/or the confirmatory trial data are not sufficient to support accelerated approval; the risk that more patient data become available that results in a different interpretation than the one derived from the year three and four data analyses, respectively; risks related to the Company’s interactions with regulatory authorities, which may affect the pathways to regulatory approval; whether RMAT designation, Breakthrough Therapy designation, or any accelerated pathway, if granted, will lead to regulatory approval; the Company’s ability to conduct and fund any required confirmatory study for ifezuntirgene inilparvovec; the Company’s ability to successfully complete any required confirmatory study for ifezuntirgene inilparvovec; the risk that accelerated approval, if granted, may be subject to post-approval requirements that are difficult or costly to satisfy; and the Company’s ability to continue to build and maintain the infrastructure and personnel needed to commercialize ifezuntirgene inilparvovec, if approved. These risks and uncertainties are more fully described under the heading “Risk Factors” in the Company’s periodic filings with the U.S. Securities & Exchange Commission (“SEC”), including its Annual Report on Form 10-K filed with the SEC on March 2, 2026, its Quarterly Report on Forms 10-Q filed with the SEC on May 5, 2026 and July 29, 2026, respectively, and in other filings that the Company makes with the SEC from time to time. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements and, except as required by law, the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.

uniQure Contacts:

FOR INVESTORS:	FOR MEDIA:
Chiara Russo	Tom Malone
Direct: 781-491-4371	Direct: 339-970-7558
Mobile: 617-306-9137	Mobile:339-223-8541
c.russo@uniQure.com	t.malone@uniQure.com

---

¹ Yohrling G, et al. Neurology 2020;94(15 Suppl):954.
² Medina A, et al. Mov Disord 2022;37(12):2327–2335
³ Furby H, et al. Eur J Neurol 2022;29(8):2249–2257.